70P - A retrospective analysis to explore the value of gemcitabine combined with cisplatin as adjuvant chemotherapy of NSCLC

Date 07 May 2017
Event ELCC 2017
Session Poster Display Session
Topics Non-Small Cell Lung Cancer
Thoracic Malignancies
Presenter Di Ma
Citation Annals of Oncology (2017) 28 (suppl_2): ii20-ii23. 10.1093/annonc/mdx085
Authors D. Ma1, J. Wang2, X. Hao1, Y. Wang1, X. Hu1, P. Xing1, J. Li1
  • 1Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN
  • 2Medical Oncology, Beijing Chaoyang Sanhuan Cancer Hospital, 100122 - Beijing/CN



To evaluate the value of gemcitabine combined with cisplatin (GP) as adjuvant chemotherapy in radical resection of non-small cell lung cancer (NSCLC).


This study reviewed the 100 patients’ charts with radical resection of NSCLC treated with cisplatin/gemcitabine as adjuvant chemotherapy between June 2007 and December 2010 in CAMS (Chinese Academy of Medical Sciences).


Among the 100 cases, eighty-two (82%) was male and the median age was 59 years (range, 36-73 years). Forty-two (42%) patients were adenocarcinoma, while fifty-five (55%) were squamous cell carcinoma. Most patients had pathologic IIB (29%) and IIIA (44%) stage disease, whereas others were IA (2%), IB (14%), IIA (6%), and IIIB (5%). Surgical methods included sleeve resection (12%), pneumonectomy (14%), and lobectomy (73%).The completion rate of 4 cycles of chemotherapy was 85%, of which 76 case (76%) completed the planned full-dose chemotherapy. And the main reason for the reduction in gemcitabine doses in thirteen patients were grade 3/4 myelosuppression, mainly neutropenia and thrombocytopenia. The median dose and dose intensity were 8377.1 mg/m2 and 708 mg/(m2·week) for gemcitabine, and 293.38 mg/m2 and 25.24 mg/(m2·week) for cisplatin respectively. With good compliance to treatment, toxicities observed were tolerable and managable. During a median follow-up duration of 73.1 months, the median disease-free survival(DFS) was 33.8 months (95%CI: 15.938-51.676). Patients with the squamous cell carcinoma (HR 0.404, 95% CI 0.241-0.676, P = 0.001) and pathologic stage I (HR 4.379, 95% CI 1.721-11.142, P = 0.002) were associated with better DFS from univariate and multivariate analyses. The survival rate at 1 year, 2 years and 5 years was 94%, 77% and 55%, while the survival rate without recurrence was 64%, 53% and 39% respectively.


As one of the adjuvant chemotherapy regimens, gemcitabine combined with cisplatin is well tolerated. Patients with squamous cell carcinomas or stage I can benefit from it better.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.